The United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) at Aurobindo Pharma’s Unit VII, a Formulation Manufacturing facility situated at Jedcherla Mandal, Mahaboob Nagar District, Telangana, from July 28 to August 4, 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI).
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
